Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CompugenCGEN +4.39%59 Debt-to-Equity is 0.03 as of Mar. 2026, which is at its 10-year median of 0.03. GuruFocus rates CGEN with a GF Score™ of 59/100 and a GF Value™ of $5.17 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 965 Biotechnology companies, Compugen ranks better than 81.14% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Compugen's Debt-to-Equity or its related term are showing as below:
CGEN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.03 Max: 0.15
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of Compugen was 0.15. The lowest was 0.02. And the median was 0.03.
CGEN's Debt-to-Equity is ranked better than 81.14% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs CGEN: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Compugen Debt-to-Equity Related Terms
Compugen Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Compugen's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CGEN vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Compugen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compugen Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Compugen's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Compugen's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compugen (CGEN) has a Debt-to-Equity of 0.03 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Compugen and its competitors. This is near median its historical median of 0.03. Over the past decade, Compugen's Debt-to-Equity has ranged from 0.02 to 0.15. According to the industry distribution chart, Compugen ranks #182 out of 965 companies in the Biotechnology industry, placing it in the top 18.9%.
Is Compugen's Debt-to-Equity too high?
Compugen's current Debt-to-Equity of 0.03 is near median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.15. The Biotechnology industry median Debt-to-Equity is 0.16. Compugen's value of 0.03 is 81.3% below this industry median. Based on the distribution chart, Compugen ranks #182 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Compugen has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Compugen's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Compugen ranks #182 out of 965 companies for Debt-to-Equity. This places Compugen in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Compugen's value of 0.03 is 81.3% below this benchmark. Historically, Compugen's own Debt-to-Equity has ranged from 0.02 to 0.15 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.16, Compugen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compugen's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Compugen and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compugen's current Debt-to-Equity is 0.03, which is near median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compugen stock overvalued right now?
Based on GuruFocus' analysis, Compugen (CGEN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.17, compared to a current price of $2.38 — trading 54% below its estimated fair value. The current Debt-to-Equity is 0.03, which is near median its 10-year median of 0.03 and 81.3% below the Biotechnology industry median of 0.16. Compugen's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Compugen (CGEN), the current Debt-to-Equity is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Compugen (CGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Compugen stock appears to be undervalued.
The current stock price of $2.38 is trading 54% below its estimated GF Value™ of $5.17.
GuruFocus considers Compugen to be Possible Value Trap.
Key valuation signals for CGEN:
Debt-to-Equity: 0.03 (near median its 10-year median of 0.03)
GF Value™: $5.17 vs. price of $2.38 (54% below fair value)
Industry Position: 81.3% below the Biotechnology median (#182 of 965)
No single metric tells the full story. See the CGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
59GF Score
Get the complete analysis for CGEN
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGEN has been successfully added to your 
